Voyager unveils genetic therapy pipeline for Alzheimer's, Parkinson's and ALS

Voyager Therapeutics will present its neurological disease portfolio on June 15th, anchored by a human-genetics-first approach that has already secured partnerships with Novartis, AstraZeneca Rare Disease, Alexion and Neurocrine Biosciences. CEO Alfred W. Sandrock Jr. will lead a fireside chat at the H.C. Wainwright Neuro Perspectives conference, detailing progress across programs targeting Alzheimer's disease, Friedreich's ataxia, Parkinson's disease and amyotrophic lateral sclerosis. The technological foundation is the TRACER AAV capsid platform, engineered to achieve high brain penetration via intravenous dosing—circumventing the blood-brain barrier that has stalled competing approaches for decades. For longevity-conscious readers tracking frontier therapies: this represents one of the rare non-invasive genetic engineering bets for halting neurodegeneration, with validation from global pharma tier-one partners.